CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 123 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03652181
NCT03652181N/ACompleted

CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness

University of Chicago·observational·Posted Aug 29, 2018·Updated Jun 27, 2024

In Brief

An observational study for CCM and 6 related conditions. Completed, enrolled 123 participants across 1 site.

Detailed Summary

Brain Cavernous Angiomas with Symptomatic Hemorrhage (CASH) are rare, but they exact a heavy burden of neurologic disability from recurrent bleeding, for which there is no proven therapy. This trial readiness project aims to address current critical obstacles in identifying cases at multiple sites, characterizing their relevant features, and measuring their outcome. The timing cannot be more opportune, with therapeutic targets already identified, exceptional collaboration among researchers and with the patient community, and several drugs ready to benefit from a track to clinical testing in the next five years.

Study Details

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedAug 29, 2018
Enrollment StartAug 20, 2018
Primary CompletionNov 3, 2022
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 7.8 years ago